Cargando…
Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status?
Background: Alzheimer’s disease (AD) is a neurodegenerative disorder that may benefit from early diagnosis and intervention. Therefore, there is a need to identify early biomarkers of AD using non-invasive techniques such as functional magnetic resonance imaging (fMRI). Recently, novel approaches to...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826397/ https://www.ncbi.nlm.nih.gov/pubmed/29515434 http://dx.doi.org/10.3389/fnagi.2018.00039 |
_version_ | 1783302346650943488 |
---|---|
author | Scarapicchia, Vanessa Mazerolle, Erin L. Fisk, John D. Ritchie, Lesley J. Gawryluk, Jodie R. |
author_facet | Scarapicchia, Vanessa Mazerolle, Erin L. Fisk, John D. Ritchie, Lesley J. Gawryluk, Jodie R. |
author_sort | Scarapicchia, Vanessa |
collection | PubMed |
description | Background: Alzheimer’s disease (AD) is a neurodegenerative disorder that may benefit from early diagnosis and intervention. Therefore, there is a need to identify early biomarkers of AD using non-invasive techniques such as functional magnetic resonance imaging (fMRI). Recently, novel approaches to the analysis of resting-state fMRI data have been developed that focus on the moment-to-moment variability in the blood oxygen level dependent (BOLD) signal. The objective of the current study was to investigate BOLD variability as a novel early biomarker of AD and its associated psychophysiological correlates. Method: Data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 2 database from 19 participants with AD and 19 similarly aged controls. For each participant, a map of BOLD signal variability (SD(BOLD)) was computed as the standard deviation of the BOLD timeseries at each voxel. Group comparisons were performed to examine global differences in resting state SD(BOLD) in AD versus healthy controls. Correlations were then examined between participant SD(BOLD) maps and (1) ADNI-derived composite scores of memory and executive function and (2) neuroimaging markers of cerebrovascular status. Results: Between-group comparisons revealed significant (p < 0.05) increases in SD(BOLD) in patients with AD relative to healthy controls in right-lateralized frontal regions. Lower memory scores and higher WMH burden were associated with greater SD(BOLD) in the healthy control group (p < 0.1), but not individuals with AD. Conclusion: The current study provides proof of concept of a novel resting state fMRI analysis technique that is non-invasive, easily accessible, and clinically compatible. To further explore the potential of SDBOLD as a biomarker of AD, additional studies in larger, longitudinal samples are needed to better understand the changes in SDBOLD that characterize earlier stages of disease progression and their underlying psychophysiological correlates. |
format | Online Article Text |
id | pubmed-5826397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58263972018-03-07 Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status? Scarapicchia, Vanessa Mazerolle, Erin L. Fisk, John D. Ritchie, Lesley J. Gawryluk, Jodie R. Front Aging Neurosci Neuroscience Background: Alzheimer’s disease (AD) is a neurodegenerative disorder that may benefit from early diagnosis and intervention. Therefore, there is a need to identify early biomarkers of AD using non-invasive techniques such as functional magnetic resonance imaging (fMRI). Recently, novel approaches to the analysis of resting-state fMRI data have been developed that focus on the moment-to-moment variability in the blood oxygen level dependent (BOLD) signal. The objective of the current study was to investigate BOLD variability as a novel early biomarker of AD and its associated psychophysiological correlates. Method: Data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 2 database from 19 participants with AD and 19 similarly aged controls. For each participant, a map of BOLD signal variability (SD(BOLD)) was computed as the standard deviation of the BOLD timeseries at each voxel. Group comparisons were performed to examine global differences in resting state SD(BOLD) in AD versus healthy controls. Correlations were then examined between participant SD(BOLD) maps and (1) ADNI-derived composite scores of memory and executive function and (2) neuroimaging markers of cerebrovascular status. Results: Between-group comparisons revealed significant (p < 0.05) increases in SD(BOLD) in patients with AD relative to healthy controls in right-lateralized frontal regions. Lower memory scores and higher WMH burden were associated with greater SD(BOLD) in the healthy control group (p < 0.1), but not individuals with AD. Conclusion: The current study provides proof of concept of a novel resting state fMRI analysis technique that is non-invasive, easily accessible, and clinically compatible. To further explore the potential of SDBOLD as a biomarker of AD, additional studies in larger, longitudinal samples are needed to better understand the changes in SDBOLD that characterize earlier stages of disease progression and their underlying psychophysiological correlates. Frontiers Media S.A. 2018-02-21 /pmc/articles/PMC5826397/ /pubmed/29515434 http://dx.doi.org/10.3389/fnagi.2018.00039 Text en Copyright © 2018 Scarapicchia, Mazerolle, Fisk, Ritchie and Gawryluk. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Scarapicchia, Vanessa Mazerolle, Erin L. Fisk, John D. Ritchie, Lesley J. Gawryluk, Jodie R. Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status? |
title | Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status? |
title_full | Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status? |
title_fullStr | Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status? |
title_full_unstemmed | Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status? |
title_short | Resting State BOLD Variability in Alzheimer’s Disease: A Marker of Cognitive Decline or Cerebrovascular Status? |
title_sort | resting state bold variability in alzheimer’s disease: a marker of cognitive decline or cerebrovascular status? |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826397/ https://www.ncbi.nlm.nih.gov/pubmed/29515434 http://dx.doi.org/10.3389/fnagi.2018.00039 |
work_keys_str_mv | AT scarapicchiavanessa restingstateboldvariabilityinalzheimersdiseaseamarkerofcognitivedeclineorcerebrovascularstatus AT mazerolleerinl restingstateboldvariabilityinalzheimersdiseaseamarkerofcognitivedeclineorcerebrovascularstatus AT fiskjohnd restingstateboldvariabilityinalzheimersdiseaseamarkerofcognitivedeclineorcerebrovascularstatus AT ritchielesleyj restingstateboldvariabilityinalzheimersdiseaseamarkerofcognitivedeclineorcerebrovascularstatus AT gawrylukjodier restingstateboldvariabilityinalzheimersdiseaseamarkerofcognitivedeclineorcerebrovascularstatus |